OTEZLA DELIVERS PROVEN AND SUSTAINED EFFICACY¹

Sustained PASI response up to 32 weeks^1,a

Week 16
(n = 501)
(n = 247)

Week 32
(n = 425)
(n = 216)

Mean Percent Improvement in
PASI Score From Baseline

62%

Sustained_PASI_improvement_up_to_32_weeks

^aESTEEM 1 study; full analysis set, data as observed.

OTEZLA improves skin clearance in biologic-naïve patients, with response maintained up to 2 years^1,2

See the OTEZLA difference

Real patients, real pictures.*

Actual patient with psoriasis before treatment with OTEZLA® (apremilast). Please see full Important Safety Information.

Baseline

Actual patient with a decrease in PASI score after 16 weeks of treatment with OTEZLA® (apremilast). Please see full Important Safety Information.

Week 16 PASI-45 result

Individual results may vary.

Actual patient with a 62% decrease in PASI score after 32 weeks of treatment with OTEZLA® (apremilast). Please see full Important Safety Information.

Week 32 PASI-68 result

Individual results may vary.

^*Photos taken from the ESTEEM clinical trial program, which evaluated OTEZLA 30 mg BID in patients with active plaque psoriasis.

BID, twice daily; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; PASI, Psoriasis Area and Severity Index.

OTEZLA DELIVERS RAPID AND SUSTAINED EFFICACY IN BIOLOGIC-NAÏVE PATIENTS^2,3†

Sustained PASI improvement up to 2 years^2,3,a

^aLIBERATE study. Data as observed among patients with a value at the time point indicated, with no imputation for missing values.

OTEZLA improves skin clearance in biologic-naïve
patients, with response maintained up to 2 years^2,3

See the multiple manifestations of psoriasis See the multiple
manifestations of psoriasis

References:

Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73:37-49.
Data on file, Amgen Inc.
Reich K, Gooderham M, Bewley A, et al. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study. J Eur Acad Dermatol Venereol. 2018;32(3):397-402.

OTEZLA DELIVERS PROVEN AND SUSTAINED EFFICACY1

Sustained PASI response up to 32 weeks1,a

See the OTEZLA difference

OTEZLA DELIVERS RAPID AND SUSTAINED EFFICACY IN BIOLOGIC-NAÏVE PATIENTS2,3†

Sustained PASI improvement up to 2 years2,3,a

References:

Approved Country Product Information

To access Summary of Product Characteristics in languages other than those listed,

United States

Canada

Australia

Israel

Switzerland

New Zealand

Austria

Belgium

Bulgaria

Croatia

Republic of Cyprus

Czech Republic

Denmark

Estonia

Finland

France

Germany

Greece

Hungary

Ireland

Italy

Latvia

Lithuania

Luxembourg

Malta

Netherlands

Poland

Portugal

Romania

Slovakia

Slovenia

Singapore

Spain

Sweden

United Kingdom

Norway

Iceland

Liechtenstein

Russia

Japan

Hong Kong

Kuwait

Taiwan

UAE

South Korea

Thailand

Lebanon

Qatar

Argentina

Mexico

Brazil

Malaysia

Oman

Saudi Arabia

OTEZLA DELIVERS PROVEN AND SUSTAINED EFFICACY¹

Sustained PASI response up to 32 weeks^1,a

OTEZLA DELIVERS RAPID AND SUSTAINED EFFICACY IN BIOLOGIC-NAÏVE PATIENTS^2,3†

Sustained PASI improvement up to 2 years^2,3,a